| systematic review | Q1504425 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1156489G |
| P356 | DOI | 10.1371/JOURNAL.PONE.0156489 |
| P932 | PMC publication ID | 4934683 |
| P698 | PubMed publication ID | 27383192 |
| P50 | author | Garrett Green | Q87831239 |
| P2093 | author name string | Loren K Mell | |
| Ruben Carmona | |||
| Kaveh Zakeri | |||
| Andrew Sharabi | |||
| Chih-Han Lee | |||
| Saif Borgan | |||
| Zaid Marhoon | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 |
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| Two-sided confidence intervals for the single proportion: comparison of seven methods | Q28271313 | ||
| Publication bias in clinical research | Q29541186 | ||
| A note on competing risks in survival data analysis | Q30951799 | ||
| Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns | Q36851212 | ||
| Survival end point reporting in randomized cancer clinical trials: a review of major journals | Q37231288 | ||
| Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. | Q37411227 | ||
| Gene-expression-based prognostic assays for breast cancer | Q37741797 | ||
| Cancer biomarkers: selecting the right drug for the right patient | Q37982927 | ||
| Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic review | Q38016057 | ||
| Cancer gene expression signatures - the rise and fall? | Q38090088 | ||
| Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794. | Q41975833 | ||
| Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: a population-based study | Q43489980 | ||
| Validated competing event model for the stage I-II endometrial cancer population | Q43733348 | ||
| On lumping, splitting, and the nosology of clinical trial populations and end points. | Q45949036 | ||
| Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? | Q51912002 | ||
| More on Cetuximab in Head and Neck Cancer | Q56775178 | ||
| Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks | Q62071396 | ||
| Reporting recommendations for tumor marker prognostic studies | Q81236405 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm | Q1216998 |
| tumor biomarker | Q66205818 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e0156489 | |
| P577 | publication date | 2016-07-06 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review | |
| P478 | volume | 11 |
Search more.